Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 6, 2010, Pages 546-554

  Arfaoui, Amira Toumi ^a   Mahmoud, Lilia Kriaa Ben ^a   Hmida, Abdelmajid Ben ^c   Khiari, Mariem ^a   Mohamed, Amine Lounis ^a   Chaar, Ines ^a   Khalfallah, Taher ^b   Regaya, Sabeh Mzabi ^b   Bouraoui, Saadia ^a,b  

^a UNIVERSITY OF TUNIS   (Tunisia)

^b MONGI SLIM HOSPITAL   (Tunisia)

^c UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

colorectal cancer; p73 polymorphism; prognosis

Indexed keywords

PROTEIN P73;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TUNISIA; WILD TYPE;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; NUCLEAR PROTEINS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS; TUNISIA;

EID: 78650447622     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e9fe58     Document Type: Article

References (36)

1. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-819. (Pubitemid 27357971)
2. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560-564. (Pubitemid 34288861)
3. Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001; 61:1598-1603.
4. Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347-2349. (Pubitemid 28252692)
5. Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076-2077. (Pubitemid 28232887)
6. Yokomizo A, Mai M, Tindall DJ, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18:1629-1633. (Pubitemid 29108063)
7. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99-103. (Pubitemid 30143141)
8. Moll UM, Erster S, Zaika A. p53, p63 and p73-solos, alliances and feuds among family members. Biochim Biophys Acta. 2001;1552: 47-59. (Pubitemid 34124130)
9. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat. 2003;21:182-191. (Pubitemid 36292961)
10. Coates PJ. Regulating p73 isoforms in human tumours. J Pathol. 2006;210:385-389.
11. Ichimiya S, Nimura Y, Kageyama H, et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene. 1999;18:1061-1066. (Pubitemid 29086283)
12. Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 1998;58:1380-1383. (Pubitemid 28193594)
13. Nimura Y, Mihara M, Ichimiya S, et al. P73, a gene related to p53, is not mutated in esophageal carcinomas. Int J Cancer. 1998;78: 437-440. (Pubitemid 28481161)
14. Cai Y, Yang GY, Nie Y, et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis. 2000;21:683-689. (Pubitemid 30214025)
15. Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res. 2002;8:165-170. (Pubitemid 34101473)
16. Guan M, Peng HX, Yu B, et al. p73 overexpression and angiogenesis in human colorectal carcinoma. Jpn J Clin Oncol. 2003;33:215-220. (Pubitemid 43115261)
17. Herath NI, Kew MC, Whitehall VL, et al. p73 is up-regulated in a subset of hepatocellular carcinomas. Hepatology. 2000;31:601-605.
18. Zaika AI, Kovalev S, Marchenko ND, et al. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 1999;59:3257-3263. (Pubitemid 29316031)
19. Hamajima N, Matsuo K, Suzuki T, et al. No association of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphism with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81-85. (Pubitemid 34326437)
20. Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499-1503. (Pubitemid 34001580)
21. Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2004;25:1911-1916. (Pubitemid 39405910)
22. Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis. 2005;26:103-107. (Pubitemid 40207704)
23. Hiraki A, Matsuo K, Hamajima N, et al. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 2003;4:107-112.
24. Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2000;10:307-311.
25. Niwa Y, Hamajima N, Atsuta Y, et al. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett. 2004;205:55-60. (Pubitemid 38230139)
26. Li H, Yao L, Ouyang T, et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis. 2007;28:372-377. (Pubitemid 46321853)
27. Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 2004;64: 6863-6866. (Pubitemid 39330992)
28. Melino G, De Laurenzi V, Vousden KH. P73: friend or foe in tumorigenesis. Nat Rev. 2002;2:605-615. (Pubitemid 37328927)
29. Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213-1223. (Pubitemid 34048476)
30. Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62:636-641. (Pubitemid 34126932)
31. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem. 2002;277: 14177-14185. (Pubitemid 34968030)
32. Lööf J, Pfeifer D, Adell G, et al. Significance of an exon 2 G4C14- to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy. Radiother Oncol. 2009;92:215-220.
33. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol. 2003;23:5540-5555. (Pubitemid 36957905)
34. Fernandez-Garcia B, Vaque JP, Herreros-Villanueva M, et al. p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ. 2007;14:254-265. (Pubitemid 46092228)
35. Melino G, Lu X, Gasco M, et al. Functional regulation of p73 and p63: development of cancer. Trends Biochem Sci. 2003;28:663-670. (Pubitemid 37500901)
36. Shan L, Yang Q, Nakamura M, et al. Frequent loss of heterozygosity at 1p36.3 and p73 abnormality in parathyroid adenomas. Mod Pathol. 2001;14:273-278. (Pubitemid 32298911)